Clarivate Introduces Epidemiology Intelligence™ for Precision Patient Population Analysis

Rhea-AI Summary

Clarivate Plc (NYSE: CLVT) has introduced Epidemiology Intelligence™, a new solution that provides biopharma companies with epidemiology, incidence, and prevalence data, along with claims-based population insights, to enhance market sizing and patient population analysis. The tool aims to address limitations in traditional research methods, offering unique insights for accurate forecasting and identification of niche populations. The launch signifies Clarivate's commitment to delivering comprehensive solutions to the life sciences and healthcare industries.

Positive

• The launch of Epidemiology Intelligence™ demonstrates Clarivate's dedication to providing innovative solutions to biopharma companies, empowering them with valuable data and insights for market analysis and strategic decision-making.

• The new solution enables clients to access comprehensive disease epidemiology coverage paired with expert analysis, facilitating faster and more accurate assessments of target patient demographics and market opportunities.

• Epidemiology Intelligence™ accelerates data-driven decision-making in the drug development lifecycle, allowing clients to validate investments, identify growth opportunities, and strategically position their products for success.

Negative

• None.

Empowering biopharma with unified epidemiology, incidence and prevalence data alongside claims-based population insights, for precise market sizing and patient population analysis

LONDON, May 7, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the launch of Epidemiology Intelligence™. The new solution combines rich insights from epidemiology, incidence and prevalence database solutions. It includes U.S. claims-based population insights to empower biopharma companies to accurately gauge market size and target patient demographics with ease.

In today's rapidly evolving market landscape, precise forecasting is essential for biopharmaceutical companies. Yet, traditional research methods often come with limitations that can lead to inaccurate estimations and costly consequences. Epidemiology Intelligence empowers users with unique insights to address critical questions about the drug-treatable population. The solution facilitates precise assessments, identification of niche populations and accurate predictions based on population insights.

Ravindra Sharma, VP Product Management, Clarivate, said: "The launch of Epidemiology Intelligence marks a significant milestone for Clarivate in our ongoing commitment to deliver comprehensive and actionable solutions to life sciences and healthcare companies. Clients can now access comprehensive coverage of disease epidemiology paired with expert analysis, seamlessly integrated into a unified platform. The new solution enables them to deliver safe, effective and commercially successful treatments to patients faster."

Epidemiology Intelligence accelerates data-driven decision-making across the drug development lifecycle. Clients can benchmark market forecasts, validate investments, pinpoint growth opportunities and utilize the solution to strategically position their products for success.

To learn more about Epidemiology Intelligence, visit here.

About Epidemiology Intelligence

Epidemiology Intelligence is a new, unified Clarivate patient population offering that brings together our legacy Epidemiology and Incidence and Prevalence Database solutions, as well as claims-based population insights, on a single platform. This transformative solution offers user-friendly visualizations, easy data exports and a unique breadth and depth of patient population insights. Conduct thorough market assessment with comprehensive coverage across 1200+ diseases and procedures. Dive deep into expert disease-specific epidemiology analysis and 10 and 20-year forecasts across 220 indications and over 5000 patient populations. Leverage expanded patient segmentation and location granularity with insights sourced from Clarivate U.S. Real-World Data.

About Clarivate
Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com

Media Contact:
Catherine Daniel
Director External Communications, Life Sciences & Healthcare
newsroom@clarivate.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/clarivate-introduces-epidemiology-intelligence-for-precision-patient-population-analysis-302136824.html

SOURCE Clarivate Plc

FAQ

What is the new solution introduced by Clarivate Plc?

Clarivate Plc has introduced Epidemiology Intelligence™.

What insights does Epidemiology Intelligence™ provide to biopharma companies?

Epidemiology Intelligence™ provides epidemiology, incidence, and prevalence data, alongside claims-based population insights, to enhance market sizing and patient population analysis.

Who is the VP Product Management at Clarivate?

Ravindra Sharma is the VP Product Management at Clarivate.

What is the stock symbol of Clarivate Plc?

The stock symbol of Clarivate Plc is CLVT.

How can clients benefit from Epidemiology Intelligence™?

Clients can benefit from Epidemiology Intelligence™ by accessing comprehensive disease epidemiology coverage, expert analysis, and faster and more accurate assessments of target patient demographics and market opportunities.